Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

18th May 2026 14:30

RNS Number : 7691E
Haleon PLC
18 May 2026
 

 

Haleon plc: Director/PDMR Shareholding 

 

18 May 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by a Person Discharging Managerial Responsibilities ("PDMR").

 

On 15 May 2026, the Company received notification of the following transaction as detailed below.

 

1

 

Details of the issuer, emission allowance market participant

 

a)

 

Name

 

Haleon plc

b)

 

LEI

 

549300PSB3WWEODCUP19 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Senior Independent Non-Executive Director

b)

 

Initial notification /Amendment

 

Initial Notification 

3

 

Details of the person discharging managerial responsibilities / person closely associated ("PCA") 

a)

 

PDMR/PCA 

PDMR 

b)

 

Name

 

Alan Stewart

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  

 

a)

 

Description of Instrument

 

 

 

Identification code

 

Share

 

 

 

GB00BMX86B70

 

b)

 

Nature of the transaction

 

Acquisition of Ordinary Shares as a result of dividend reinvestment

 

 

c)

 

Currency, Price(s) and volume(s)

Price(s) 

Volume(s) 

£3.3105

498

d)

 

Aggregated information

- Aggregated volume 

N/A

- Price 

e)

 

Date of the transaction

 

14 May 2026

 

f)

 

Place of the transaction

 

London Stock Exchange (XLON) 

 

 

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.

 

For more information, please visit www.haleon.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBDGDUIUBDGLI

Related Shares:

Haleon
FTSE 100 Latest
Value10,330.55
Change6.80